Neurocrine Biosciences (NBIX) Stock Forecast, Price Target & Predictions
NBIX Stock Forecast
Neurocrine Biosciences stock forecast is as follows: an average price target of $147.35 (represents a 19.51% upside from NBIX’s last price of $123.29) and a rating consensus of 'Buy', based on 19 wall street analysts offering a 1-year stock forecast.
NBIX Price Target
NBIX Analyst Ratings
Buy
Neurocrine Biosciences Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Oct 31, 2024 | Evan David Seigerman | BMO Capital | $121.00 | $120.27 | 0.61% | -1.86% |
Oct 22, 2024 | Jay Olson | Oppenheimer | $192.00 | $116.57 | 64.71% | 55.73% |
Oct 10, 2024 | Danielle Brill | Raymond James | $155.00 | $111.62 | 38.86% | 25.72% |
Sep 13, 2024 | Evan David Seigerman | BMO Capital | $128.00 | $122.29 | 4.67% | 3.82% |
Sep 09, 2024 | Carter Gould | Barclays | $160.00 | $120.17 | 33.14% | 29.78% |
Aug 29, 2024 | Brian Abrahams | RBC Capital | $136.00 | $123.76 | 9.89% | 10.31% |
Aug 29, 2024 | David Amsellem | Piper Sandler | $159.00 | $128.43 | 23.80% | 28.96% |
Jul 12, 2024 | Jeffrey Hung | Morgan Stanley | $170.00 | $146.50 | 16.04% | 37.89% |
Jun 06, 2024 | Brian Abrahams | RBC Capital | $141.00 | $133.69 | 5.47% | 14.36% |
May 28, 2024 | Ashwani Verma | UBS | $193.00 | $139.40 | 38.45% | 56.54% |
10
Neurocrine Biosciences Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 2 | 7 | 15 |
Avg Price Target | $156.50 | $150.14 | $161.60 |
Last Closing Price | $123.29 | $123.29 | $123.29 |
Upside/Downside | 26.94% | 21.78% | 31.07% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 29, 2024 | RBC Capital | Market Perform | Market Perform | Hold |
Oct 29, 2024 | Raymond James | Underperform | Underperform | Hold |
Oct 22, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Oct 14, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Oct 04, 2024 | Piper Sandler | Underperform | Underperform | Hold |
Oct 04, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
Sep 13, 2024 | William Blair | Outperform | Outperform | Hold |
Sep 13, 2024 | BMO Capital | Market Perform | Market Perform | Hold |
Sep 09, 2024 | RBC Capital | Market Perform | Market Perform | Hold |
Sep 09, 2024 | Piper Sandler | Underperform | Underperform | Hold |
10
Neurocrine Biosciences Financial Forecast
Neurocrine Biosciences Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $498.80M | $452.70M | $420.40M | $412.00M | $387.90M | $378.20M | $310.60M | $312.00M | $296.00M | $288.90M | $236.60M | $247.90M | $258.50M | $302.40M | $237.10M | $244.01M | $222.09M |
Avg Forecast | $899.46M | $868.51M | $836.75M | $798.88M | $742.24M | $705.85M | $672.04M | $624.95M | $629.55M | $600.64M | $545.98M | $512.40M | $518.52M | $479.09M | $447.34M | $410.66M | $408.87M | $377.00M | $342.33M | $304.07M | $317.49M | $297.83M | $273.19M | $250.67M | $260.45M | $282.70M | $261.31M | $226.53M | $231.54M | $211.97M |
High Forecast | $926.56M | $894.68M | $861.96M | $822.94M | $764.60M | $727.11M | $692.28M | $650.08M | $635.90M | $601.79M | $545.98M | $512.40M | $522.66M | $506.87M | $460.81M | $423.03M | $421.19M | $377.00M | $342.33M | $304.07M | $317.49M | $297.83M | $273.19M | $250.67M | $260.45M | $282.70M | $261.31M | $226.53M | $231.54M | $211.97M |
Low Forecast | $880.12M | $849.84M | $818.76M | $781.70M | $726.28M | $690.67M | $657.59M | $608.16M | $624.80M | $599.48M | $545.98M | $512.40M | $513.94M | $279.75M | $437.72M | $401.83M | $400.08M | $377.00M | $342.33M | $304.07M | $317.49M | $297.83M | $273.19M | $250.67M | $260.45M | $282.70M | $261.31M | $226.53M | $231.54M | $211.97M |
# Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 16 | 8 | 6 | 6 | 12 | 23 | 13 | 12 | 19 | 18 | 17 | 16 | 11 | 11 | 11 | 22 | 11 | 5 | 9 | 6 | 4 | 4 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 1.01% | 1.02% | 1.01% | 1.03% | 1.10% | 1.02% | 0.98% | 0.99% | 1.06% | 0.94% | 0.95% | 0.91% | 1.16% | 1.05% | 1.05% | 1.05% |
Forecast
Neurocrine Biosciences EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 16 | 8 | 6 | 6 | 12 | 23 | 13 | 12 | 19 | 18 | 17 | 16 | 11 | 11 | 11 | 22 | 11 | 5 | 9 | 6 | 4 | 4 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $141.20M | $73.60M | $29.70M | $103.40M | $91.80M | $58.60M | $6.40M | $-4.20M | $39.90M | $66.30M | $36.10M | $51.70M | $-46.40M | $93.60M | $49.20M | $48.86M | $68.45M |
Avg Forecast | $215.88M | $208.45M | $200.83M | $191.74M | $178.14M | $169.41M | $161.30M | $149.99M | $151.10M | $144.16M | $131.04M | $47.57M | $124.45M | $114.99M | $107.37M | $43.24M | $-8.86M | $88.35M | $80.22M | $39.31M | $74.40M | $69.80M | $64.02M | $48.84M | $61.04M | $66.25M | $61.24M | $62.87M | $54.26M | $49.68M |
High Forecast | $222.38M | $214.73M | $206.88M | $197.52M | $183.51M | $174.52M | $166.16M | $156.03M | $152.62M | $144.44M | $131.04M | $57.08M | $125.44M | $121.65M | $110.60M | $51.89M | $-7.09M | $88.35M | $80.22M | $47.17M | $74.40M | $69.80M | $64.02M | $58.61M | $61.04M | $66.25M | $61.24M | $75.44M | $54.26M | $49.68M |
Low Forecast | $211.24M | $203.97M | $196.51M | $187.62M | $174.31M | $165.77M | $157.83M | $145.97M | $149.96M | $143.88M | $131.04M | $38.05M | $123.35M | $67.14M | $105.06M | $34.59M | $-10.63M | $88.35M | $80.22M | $31.45M | $74.40M | $69.80M | $64.02M | $39.07M | $61.04M | $66.25M | $61.24M | $50.29M | $54.26M | $49.68M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.23% | 0.69% | 0.69% | -11.67% | 1.04% | 0.73% | 0.16% | -0.06% | 0.57% | 1.04% | 0.74% | 0.85% | -0.70% | 1.53% | 0.78% | 0.90% | 1.38% |
Forecast
Neurocrine Biosciences Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 16 | 8 | 6 | 6 | 12 | 23 | 13 | 12 | 19 | 18 | 17 | 16 | 11 | 11 | 11 | 22 | 11 | 5 | 9 | 6 | 4 | 4 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $83.10M | $95.50M | $-76.60M | $89.00M | $68.50M | $-16.90M | $13.90M | $-7.30M | $22.50M | $42.30M | $32.10M | $347.90M | $-57.60M | $79.60M | $37.40M | $34.00M | $53.79M |
Avg Forecast | $285.47M | $264.78M | $249.49M | $217.75M | $199.55M | $171.31M | $159.06M | $145.74M | $167.69M | $158.19M | $117.69M | $24.22M | $126.41M | $108.41M | $84.96M | $22.02M | $-15.40M | $84.11M | $63.26M | $20.02M | $70.39M | $57.85M | $52.15M | $43.43M | $62.49M | $-2.02M | $68.70M | $47.79M | $80.68M | $68.98M |
High Forecast | $296.65M | $275.15M | $259.26M | $226.27M | $207.37M | $178.02M | $165.29M | $170.99M | $203.77M | $159.99M | $117.70M | $29.06M | $161.09M | $149.34M | $88.29M | $26.42M | $-12.32M | $84.11M | $63.26M | $24.02M | $70.39M | $57.85M | $52.15M | $52.12M | $62.49M | $-2.02M | $68.70M | $57.35M | $80.68M | $68.98M |
Low Forecast | $277.49M | $257.37M | $242.51M | $211.66M | $193.98M | $166.52M | $154.61M | $121.64M | $141.16M | $156.40M | $117.67M | $19.38M | $46.98M | $38.72M | $82.59M | $17.61M | $-18.48M | $84.11M | $63.26M | $16.01M | $70.39M | $57.85M | $52.15M | $34.74M | $62.49M | $-2.02M | $68.70M | $38.23M | $80.68M | $68.98M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.77% | 1.12% | -3.48% | -5.78% | 0.81% | -0.27% | 0.69% | -0.10% | 0.39% | 0.81% | 0.74% | 5.57% | 28.56% | 1.16% | 0.78% | 0.42% | 0.78% |
Forecast
Neurocrine Biosciences SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 16 | 8 | 6 | 6 | 12 | 23 | 13 | 12 | 19 | 18 | 17 | 16 | 11 | 11 | 11 | 22 | 11 | 5 | 9 | 6 | 4 | 4 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $204.20M | $221.80M | $242.70M | $182.90M | $186.30M | $182.80M | $200.70M | $156.50M | $154.60M | $143.20M | $129.00M | $106.50M | $112.50M | $96.50M | $117.80M | $101.21M | $84.49M |
Avg Forecast | $423.50M | $408.92M | $393.97M | $376.14M | $349.47M | $332.34M | $316.42M | $294.25M | $296.41M | $282.80M | $257.06M | $349.70M | $244.14M | $225.57M | $210.62M | $317.91M | $330.19M | $177.50M | $161.18M | $289.01M | $149.49M | $140.23M | $128.62M | $174.53M | $122.63M | $133.10M | $123.04M | $150.52M | $109.02M | $99.80M |
High Forecast | $436.25M | $421.24M | $405.84M | $387.47M | $360.00M | $342.35M | $325.95M | $306.08M | $299.40M | $283.34M | $257.06M | $419.64M | $246.08M | $238.65M | $216.97M | $381.49M | $396.23M | $177.50M | $161.18M | $346.81M | $149.49M | $140.23M | $128.62M | $209.44M | $122.63M | $133.10M | $123.04M | $180.63M | $109.02M | $99.80M |
Low Forecast | $414.39M | $400.13M | $385.50M | $368.05M | $341.95M | $325.19M | $309.61M | $286.34M | $294.17M | $282.25M | $257.06M | $279.76M | $241.98M | $131.72M | $206.09M | $254.33M | $264.15M | $177.50M | $161.18M | $231.21M | $149.49M | $140.23M | $128.62M | $139.62M | $122.63M | $133.10M | $123.04M | $120.42M | $109.02M | $99.80M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 1.05% | 0.76% | 0.55% | 1.05% | 1.13% | 0.69% | 1.05% | 1.10% | 1.11% | 0.74% | 0.87% | 0.85% | 0.78% | 0.78% | 0.93% | 0.85% |
Forecast
Neurocrine Biosciences EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 16 | 8 | 6 | 6 | 12 | 23 | 13 | 12 | 19 | 18 | 17 | 16 | 11 | 11 | 11 | 22 | 11 | 5 | 9 | 6 | 4 | 4 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.85 | $0.98 | $-0.79 | $0.92 | $0.72 | $-0.18 | $0.15 | $-0.08 | $0.24 | $0.45 | $0.34 | $3.72 | $-0.62 | $0.86 | $0.40 | $0.37 | $0.59 |
Avg Forecast | $2.74 | $2.54 | $2.39 | $2.09 | $1.91 | $1.64 | $1.53 | $1.40 | $1.61 | $1.52 | $1.13 | $1.10 | $1.21 | $1.04 | $0.81 | $0.62 | $1.12 | $0.81 | $0.61 | $0.35 | $0.68 | $0.56 | $0.50 | $0.53 | $0.60 | $-0.02 | $0.66 | $0.52 | $0.78 | $0.66 |
High Forecast | $2.84 | $2.64 | $2.49 | $2.17 | $1.99 | $1.71 | $1.58 | $1.64 | $1.95 | $1.53 | $1.13 | $1.10 | $1.54 | $1.43 | $0.85 | $0.64 | $1.16 | $0.81 | $0.61 | $0.35 | $0.68 | $0.56 | $0.50 | $0.53 | $0.60 | $-0.02 | $0.66 | $0.52 | $0.78 | $0.66 |
Low Forecast | $2.66 | $2.47 | $2.33 | $2.03 | $1.86 | $1.60 | $1.48 | $1.17 | $1.35 | $1.50 | $1.13 | $1.10 | $0.45 | $0.37 | $0.79 | $0.60 | $1.09 | $0.81 | $0.61 | $0.35 | $0.68 | $0.56 | $0.50 | $0.53 | $0.60 | $-0.02 | $0.66 | $0.52 | $0.78 | $0.66 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.82% | 1.20% | -1.28% | 0.82% | 0.89% | -0.30% | 0.43% | -0.11% | 0.43% | 0.90% | 0.64% | 6.19% | 31.94% | 1.30% | 0.77% | 0.48% | 0.89% |
Forecast
Neurocrine Biosciences Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
IRWD | Ironwood Pharmaceuticals | $3.52 | $11.67 | 231.53% | Buy |
PCRX | Pacira BioSciences | $17.03 | $35.00 | 105.52% | Hold |
DVAX | Dynavax | $12.17 | $24.50 | 101.31% | Buy |
AVDL | Avadel Pharmaceuticals | $10.75 | $17.80 | 65.58% | Buy |
EVO | Evotec SE | $5.30 | $8.00 | 50.94% | Buy |
AMPH | Amphastar Pharmaceuticals | $44.09 | $66.00 | 49.69% | Buy |
ANIP | ANI Pharmaceuticals | $55.10 | $79.00 | 43.38% | Buy |
COLL | Collegium Pharmaceutical | $30.00 | $40.50 | 35.00% | Buy |
ALKS | Alkermes | $27.91 | $36.38 | 30.35% | Hold |
NBIX | Neurocrine Biosciences | $123.29 | $147.35 | 19.51% | Buy |
ITCI | Intra-Cellular Therapies | $85.64 | $94.50 | 10.35% | Buy |
PBH | Prestige Consumer Healthcare | $82.67 | $89.50 | 8.26% | Buy |
SUPN | Supernus Pharmaceuticals | $36.12 | $38.00 | 5.20% | Buy |
DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |